Results 61 to 70 of about 49,935 (237)

Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. [PDF]

PLoS ONE, 2017
We evaluated the efficacy and safety of tofacitinib in patients with rheumatoid arthritis (RA) in a real-world setting.Seventy consecutive patients, for whom tofacitinib was initiated between November 2013 and May 2016, were enrolled.
Naoki Iwamoto, Sosuke Tsuji, Ayuko Takatani, Toshimasa Shimizu, Shoichi Fukui, Masataka Umeda, Ayako Nishino, Yoshiro Horai, Tomohiro Koga, Shin-Ya Kawashiri, Toshiyuki Aramaki, Kunihiro Ichinose, Yasuko Hirai, Mami Tamai, Hideki Nakamura, Kaoru Terada, Tomoki Origuchi, Katsumi Eguchi, Yukitaka Ueki, Atsushi Kawakami   +19 more
doaj   +1 more source

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate

, 2022
S.e28-e39Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis.
Gladman, D.D., Kanik, K.S., Menon, S., Kivitz, A.J., Wu, J., Shirinsky, I., Fleishaker, D., Behrens, F., Coates, L.C., Hsu, M.-A., Wang, C., Nash, P., Mease, P.J., Romero, A.B., Wei, J.C., Fallon, L.   +15 more
core   +1 more source

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib+ substudy of opal balance

, 2020
Background: Tofacitinib is an oral JAK inhibitor for the treatment of psoriatic arthritis (PsA). Objectives: To assess tofacitinib 5 mg BID as monotherapy after methotrexate (MTX) withdrawal vs with continued background MTX in patients (pts) with PsA ...
Mease, PJ, Nash, P, Romero, AB, Wu, J, Wang, C, Hsu, MA, Coates, LC, Fleishaker, D, Kivitz, A, Behrens, F, Gladman, DD, Fallon, L, Wei, JCC, Kanik, K   +13 more
core  

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz, Seza Ozen, Hacer Neslihan Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet Emin Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet Orhan Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Tofacitinib-Associated Cerebral Venous Sinus Thrombosis.

, 2021
Tofacitinib is a Janus kinase inhibitor indicated to treat adult patients with moderately to severely active ulcerative colitis (UC). Although thrombosis is a known adverse event of tofacitinib, there are no reports specific to cerebral venous sinus ...
Gofman, Natalie, Brown, Danielle, Fitzgerald, Ethan, Hakma, Zakaria, MD   +3 more
core   +1 more source

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies [PDF]

, 2018
Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This post hoc analysis assessed the efficacy of tofacitinib using pooled data from two phase 3 studies of patients with active PsA.Data were pooled from OPAL ...
Sujatha Menon (3513110), Nash, P, Ports, William C, Laura C. Coates (5081063), Menon, Sujatha, Kanik, KS, Peter Nash (473901), Cunshan Wang (441330), Wang, C, Papp, Kim A., Roy Fleischmann (96247), Keith S. Kanik (5855156), Coates, LC, Ports, WC, Papp, Kim A, Coates, Laura C., William C. Ports (5855158), Hendrikx, Thijs, Gomez-Reino, JJ, Wang, Cunshan, Jesus Gomez-Reino, Juan, Juan Jesus Gomez-Reino (5855153), Coates, Laura, Papp, KA, Joseph Wu (655119), Wu, J, Kanik, Keith S., Nash, Peter, Wu, Joseph, Ports, William C., Kanik, Keith S, Fleischmann, R, Thijs Hendrikx (5855157), Coates, Laura C, Menon, S, Kim A. Papp (5855150), Hendrikx, T, Fleischmann, Roy   +37 more
core   +1 more source

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Nonmelanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with JAK inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Methods This study used data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis linked to the
Zixing Tian, Lianne Kearsley‐Fleet, Sizheng Steven Zhao, James Galloway, Mark Lunt, Kath Watson, Narges Azadbakht, British Society for Rheumatology Biologics Register in Rheumatoid Arthritis Contributors Group, Kimme L. Hyrich   +8 more
wiley   +1 more source

Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis

Advances in Rheumatology
Objectives Describe tofacitinib safety from an integrated analysis of randomized controlled trials (RCTs) in patients with ankylosing spondylitis (AS). Method Pooled data from Phase 2 (NCT01786668; 04/2013–03/2015)/Phase 3 (NCT03502616; 06/2018–08/2020 ...
Atul Deodhar, Servet Akar, Jeffrey R. Curtis, Bassel El-Zorkany, Marina Magrey, Cunshan Wang, Joseph Wu, Solomon B. Makgoeng, Ivana Vranic, Sujatha Menon, Dona L. Fleishaker, Annette M. Diehl, Lara Fallon, Arne Yndestad, Robert B. M. Landewé   +14 more
doaj   +1 more source

Tofacitinib in psoriatic arthritis

, 2017
Psoriatic arthritis is a heterogeneous disease that has been difficult to manage until the recent advent of biologics. However, there are still unmet medical needs for newer agents.
Tsen-Fang Tsai, Ting-Shun Wang
core   +1 more source